Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 4 Association between preclinical AD stages and conversion to MCI/DAT

From: Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition

Neuronal injury marker Percentage of subjects in each category Total number of subjects (Subjects who progressed) Hazard ratio (95% CI) p-value
Combined-NI Stage 0: 31.9% 76 (7) Ref. Ref.
  Stage 1: 15.1% 36 (5) 2.6 (0.8-8.6) 0.12
  Stage 2: 21.8% 52 (6) 1.8 (0.5-6.3) 0.34
  Stage 3: 3.4% 8 (2) 11.3 (1.9-66.9) 0.0072
  SNAP: 22.7% 54 (8) 2.4 (0.8-6.9) 0.12
  SCINIB: 5.0% 12 (2) 4.9 (0.8-29.1) 0.078
  1. Cox hazards models were adjusted for age, gender and APOE ϵ4 presence.